Cell Therapeutics, Inc. (NASDAQ: CTICD) has long been a controversial stock. It has brought many rewards for investors and it has also brought much pain to investors. We recently featured its positive development in pixantrone with an appeal at the FDA that will allow it to resubmit a new drug application. Keep in mind that the company recently went through a reverse stock split.
Today brings news that Cell Therapeutics, being “consistent with its previously announced pipeline strategy,” has identified a potential acquisition opportunity. Most companies do not telegraph what they are trying to buy and how great the benefits are because they might actually drive the price up. Who wants to bid against themselves?
Cell Therapeutics has said its acquisition opportunity is a phase II drug candidate under study in cancer immunotherapy as protein therapeutics activating macrophages and dendritic cells “to present foreign antigens to T-killer cells and T-memory cells thus activating a tumor specific immune attack with potential lifelong immunity against the cancer.”
The company noted that this is tumor-specific and is an individualized approach for harnessing a patient’s immune system to fight and potentially eradicate cancer. For the company to try to announce that it looks forward to further discussion and to conducting due diligence, this seems like another capital raise is coming.
Another reminder was made about the company having two of its drug candidates in American Society of Clinical Oncology presentations in a week. One is interim data from a study with OPAXIO™ in patients with newly diagnosed high-grade gliomas, and another is interim study results of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia.
Most shares tank after their reverse stock splits. These shares went ex-split on a 1-for-6 split just on May 16, 2011 and the stock went from an adjusted $1.62 to $1.59 on that day. Shares are up over 1% so far this morning at $2.12, and the highs in the last week were $2.40 intra-day and $2.26 for a closing price.
JON C. OGG
The Average American Has No Idea How Much Money You Can Make Today (Sponsor)
The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.
But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.
Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account from Sofi. Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.